EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

SARS‐CoV‐2 Neutralization Breadth Is Shaped by Variant Exposure and Immune History

Greta Vizgirda, Alexander P Underwood, Ulrik Fahnøe, Christina Sølund, Signe Lysemose Villadsen, Andrea Galli, Nina Weis, Jens Bukh iD

Journal of Medical Virology · 2026

DOI: 10.1002/jmv.71054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2026. Verfasst von Greta Vizgirda und 7 weiteren Autor:innen. Beteiligte Einrichtung: Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre and Department of Immunology and…. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, SARS-CoV-2, Antibodies, Viral, COVID-19. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk Foundation, Danmarks Frie Forskningsfond, The Danish Agency for Science and Higher Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite widespread COVID‐19 vaccination, emerging SARS‐CoV‐2 variants continue to evade neutralizing responses. To determine how exposure history influences neutralizing breadth against SARS‐CoV‐2, plasma collected from 46 participants in the Clinical, Virological and Immunological COVID‐19 study cohort (CVIC) was analyzed. Participants were categorized into six groups reflecting distinct SARS‐CoV‐2 exposure profiles: individuals infected with either Wuhan‐Hu‐1 or Delta variants, infection‐naïve individuals who received two or four doses of mRNA vaccine (including a bivalent BA.4/5 booster), previously infected individuals subsequently vaccinated, and individuals with four vaccine doses plus breakthrough Omicron infection. Neutralizing breadth was assessed using a pseudoparticle panel representing major variants of interest/concern (Alpha, Beta, Gamma, Delta, Lambda, and Kappa) and a panel of representative Omicron subvariants (BA.1, BA.2, BA.5, BA.2.75, BA.2.86, BQ.1, XBB.1.5, EG.5, HV.1, and JN.1). Primary exposure through infection elicited potent homologous but variable heterologous neutralization, whereas vaccination alone induced lower yet more consistent responses across variants. Additional antigenic exposures, through either repeated vaccination or breakthrough infection, markedly enhanced cross‐variant neutralization, with the greatest potency and breadth of neutralizing responses observed in individuals with the highest number of SARS‐CoV‐2 exposures. Nonetheless, neutralizing activity against more recently emerged Omicron subvariants, including EG.5, HV.1, and JN.1, remained low. Taken together, these findings demonstrate that both the nature and number of antigenic exposures can shape the potency and breadth of SARS‐CoV‐2 neutralizing responses. While cumulative exposures improve cross‐variant immunity, ongoing viral evolution continues to erode neutralization capacity, emphasizing the need for continued variant monitoring and periodic vaccine reformulation to maintain population‐level protection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, NeutralizingSARS-CoV-2Antibodies, ViralCOVID-19HumansFemaleCOVID-19 VaccinesBreakthrough InfectionsMaleAdultMiddle AgedNeutralization TestsVaccination

Stichwörter der Autor:innen

COVID‐19SARS‐CoV‐2infectionneutralizationvaccination

Substanzen

Antibodies, NeutralizingAntibodies, ViralCOVID-19 Vaccines

Autor:innen und Institutionen

  • Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of C…
  • Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark.
  • The Kirby Institute and School of Biomedical Sciences, Faculty of Medicine and Health, UNSW Sydney, New South Wales, Australia.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Virology and Microbiological Preparedness, Statens Serum Institut, Copenhagen, Denmark.

ORCID-Profile: Jens Bukh

Förderung

  • Novo Nordisk Foundation
  • Danmarks Frie Forskningsfond
  • The Danish Agency for Science and Higher Education
  • Mauritzen La Fontaine Familiefond
  • Mauritzen La Fontaine Fonden
  • Kræftens Bekæmpelse
  • Novo Nordisk Fonden

Zitieren

APA

Vizgirda, G., Underwood, A. P., Fahnøe, U., Sølund, C., Villadsen, S. L., Galli, A., Weis, N., & Bukh, J. (2026). SARS‐CoV‐2 Neutralization Breadth Is Shaped by Variant Exposure and Immune History. Journal of Medical Virology. https://doi.org/10.1002/jmv.71054

Vancouver

Vizgirda G, Underwood AP, Fahnøe U, Sølund C, Villadsen SL, Galli A, et al. SARS‐CoV‐2 Neutralization Breadth Is Shaped by Variant Exposure and Immune History. Journal of Medical Virology. 2026. doi:10.1002/jmv.71054

BibTeX
@article{Vizgirda2026,
  author = {Vizgirda, Greta and Underwood, Alexander P and Fahnøe, Ulrik and Sølund, Christina and Villadsen, Signe Lysemose and Galli, Andrea and Weis, Nina and Bukh, Jens},
  title = {SARS‐CoV‐2 Neutralization Breadth Is Shaped by Variant Exposure and Immune History},
  journal = {Journal of Medical Virology},
  year = {2026},
  doi = {10.1002/jmv.71054}
}
Kostenlos starten →